764 Results of Andante, a Randomized Clinical Study With an Anti-IL6 Antibody (PF-04236921) in Subjects With Crohn's Disease Who Are Anti-TNF Inadequate Responders
Silvio Danese(IRCCS Ospedale San Raffaele), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Séverine Vermeire(KU Leuven), Rupert W. Leong(The University of Sydney), Cheryl Li, Fabio Cataldi(Pfizer (United States)), Gail M. Comer(Pfizer (United States)), Mary K. Maguire(Pfizer (United States)), Gerhard Rogler(University Hospital of Zurich), Gerald Fraser, Paul Hellstern(Clinical Research Atlanta), Pierre Desreumaux(Active Biotech (Sweden)), Jean S. Beebe, Anindita Banerjee(Pfizer (United States)), Anna Kohn, Natalie Rath, Remo Panaccione(University of Calgary)
Cited by 7
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
|Nature Genetics|2009|1.4k